Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 628

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

Ueno, Hideki, Ioka, Tatsuya, Ikeda, Masafumi, Ohkawa, Shinichi, Yanagimoto, Hiroaki, Boku, Narikazu, Fukutomi, Akira, Sugimori, Kazuya, Baba, Hideo, Yamao, Kenji, Shimamura, Tomotaka, Sho, Masayuki, Kitano, Masayuki, Cheng, Ann-Lii, Mizumoto, Kazuhiro, Chen, Jen-Shi, Furuse, Junji, Funakoshi, Akihiro, Hatori, Takashi, Yamaguchi, Taketo, Egawa, Shinichi, Sato, Atsushi, Ohashi, Yasuo, Okusaka, Takuji, Tanaka, Masao·2013·Journal of Clinical Oncology

Abstract

Purpose: The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority of gemcitabine plus S-1 compared with gemcitabine alone with respect to overall survival. Patients and Methods: The participants were chemotherapy-naive patients with locally advanced or metastatic pancreatic cancer. Patients were randomly assigned to receive only gemcitabine (1,000 mg/m 2 on days 1, 8, and 15 of a 28-day cycle), only S-1 (80, 100, or 120 mg/d according to body-surface area on days 1 through 28 of a 42-day cycle), or gemcitabine plus S-1 (gemcitabine 1,000 mg/m 2 on days 1 and 8 plus S-1 60, 80, or 100 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle). Results: In the total of 834 enrolled patients, median overall survival was 8.8 months in the gemcitabine group, 9.7 months in the S-1 group, and 10.1 months in the gemcitabine plus S-1 group. The noninferiority of S-1 to gemcitabine was demonstrated (hazard ratio, 0.96; 97.5% CI, 0.78 to 1.18; P < .001 for noninferiority), whereas the superiority of gemcitabine plus S-1 was not (hazard ratio, 0.88; 97.5% CI, 0.71 to 1.08; P = .15). All treatments were generally well tolerated, although hematologic and GI toxicities were more severe in the gemcitabine plus S-1 group than in the gemcitabine group. Conclusion: Monotherapy with S-1 demonstrated noninferiority to gemcitabine in overall survival with good tolerability and presents a convenient oral alternative for locally advanced and metastatic pancreatic cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.43.3680

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 628

Metadata

Authors
Ueno, H., Ioka, T., Ikeda, M., Ohkawa, S., Yanagimoto, H., Boku, N., Fukutomi, A., Sugimori, K., Baba, H., Yamao, K., Shimamura, T., Sho, M., Kitano, M., Cheng, A.-L., Mizumoto, K., Chen, J.-S., Furuse, J., Funakoshi, A., Hatori, T., Yamaguchi, T., Egawa, S., Sato, A., Ohashi, Y., Okusaka, T., & Tanaka, M.
Venue
Journal of Clinical Oncology
Published
2013-05-01
Volume
31
Issue
13
Pages
1640-1648
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2143953275
Cited by
628
References
26
FWCI
30.99
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study. https://app.cochat.ai/papers/10.1200/jco.2012.43.3680
The paper
Ueno, H., Ioka, T., Ikeda, M., Ohkawa, S., Yanagimoto, H., Boku, N., Fukutomi, A., Sugimori, K., Baba, H., Yamao, K., Shimamura, T., Sho, M., Kitano, M., Cheng, A.-L., Mizumoto, K., Chen, J.-S., Furuse, J., Funakoshi, A., Hatori, T., . . . Tanaka, M. (2013). Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.43.3680

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.